US2019015493A1PendingUtilityA1
Adherent cancer cell line expressing a hematological tumor antigen
Est. expiryJun 1, 2036(~9.9 yrs left)· nominal 20-yr term from priority
Inventors:Lijun Wu
C12N 5/0602C12N 2503/02C07K 14/70503C07K 2317/622C07K 2319/33C12N 2740/16043C12N 2503/00C07K 16/2809C12N 15/09C12N 5/0693C12N 2510/00G01N 33/4915G01N 33/5011C07K 2319/03C07K 2317/73C07K 2317/70C12N 2015/8572C12N 2510/02C07K 14/4748A61K 39/0011A61K 2039/5156A61K 2039/5154A61K 2039/5152A61K 40/4224A61K 40/4221A61K 40/4212A61K 40/4211A61K 40/31A61K 40/15A61K 40/11A61K 2239/48C12N 2501/405
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for measuring cytotoxicity of CD19-CAR T cells, comprising:
seeding transduced Hela cancer cells that stably express CD19 on a plate, adding CD19-CAR T cells to the plate, and measuring real time cytotoxicity of the CD19-CAR T cells.
2 . The method of claim 1 , wherein the CAR comprises CD19 scFv, CD28-transmembrane domain, CD28 activation domain, and CD3 zeta.
3 . The method of claim 1 , wherein the CAR further comprises a FLAG tag.Join the waitlist — get patent alerts
Track US2019015493A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.